Business Context and Reporting Period
Company: Marker Therapeutics, Inc. (MRKR)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: A clinical-stage immuno-oncology company developing Multi-Antigen Recognizing (MAR)-T cell therapies for hematological malignancies and solid tumors. The company has no commercial product revenue and relies on grants and capital raises.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 |
|---|---|---|
| Revenue | $0 | $0 |
| Grant Income | $681,579 | $1,433,270 |
| Net Loss | $(1,826,229) | $(5,005,507) |
| Net Loss Per Share (Basic/Diluted) | $(0.09) | $(0.26) |
| Cash, Cash Equivalents, & Restricted Cash | $11,922,332 (as of June 30, 2026) | N/A |
| Working Capital | $12,165,464 (as of June 30, 2026) | N/A |
| Net Cash Used in Operating Activities | N/A | $(5,120,515) |
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses decreased significantly. For the six months ended June 30, 2026, expenses were $6.7 million compared to $10.1 million in the prior year period (a 34% decrease).
- R&D Expenses: Decreased 41% to $4.3 million (six months), driven by a $2.8 million reduction in clinical trial expenses.
- G&A Expenses: Increased slightly by 3% to $2.4 million (six months), primarily due to headcount-related costs.
- One-Time Items: The prior year period included a $453,135 loss on the early termination of a vendor agreement (Cell Ready), which did not recur in the current period.
- Grant Income: Increased 18% to $1.4 million for the six months ended June 30, 2026, compared to $1.2 million in the prior year.
- Liquidity: Cash and cash equivalents decreased from $17.0 million at December 31, 2025, to $11.9 million at June 30, 2026.
Outlook, Risks, and Management Commentary
- Going Concern: The filing explicitly states that factors raise "substantial doubt" regarding the Company's ability to continue as a going concern. Management anticipates funding operations only into the second quarter of 2027 without additional capital or grants.
- Capital Strategy: The Company plans to raise additional capital through equity issuances and grant applications. An At-The-Market (ATM) offering agreement exists but had no activity during the period.
- Recent Developments:
- In July 2026 (subsequent event), the Company received a $4.2 million grant from the U.S. Department of War (formerly Department of Defense) for MT-601 clinical investigation.
- In May 2026, authorized common stock was increased from 30 million to 130 million shares.
- Risks:
- IRS Penalties: The Company received notices for approximately $0.5 million in penalties related to late 401(k) filings. No liability has been recorded as payment is not deemed probable, but the outcome is uncertain.
- Revenue Sharing: CPRIT grants require revenue sharing of low-to-mid single digits on net sales until 400% of grant funds are repaid, followed by a 0.5% perpetual royalty.
- Manufacturing: Reliance on third-party CDMOs (Cellipont) for scale-up; BCM continues to supply products for current trials.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the "second quarter of 2027" liquidity estimate given the $5.1 million cash burn in the first half of 2026.
- Grant Reliance: Assess the certainty of receiving remaining funds from awarded grants (CPRIT, NIH, FDA) and the likelihood of securing new grants to extend the runway.
- IRS Contingency: Monitor the status of the $0.5 million IRS penalty assessment and the outcome of abatement requests.
- Dilution Risk: Review the impact of outstanding warrants (approx. 7.7 million shares) and potential future equity raises on shareholder dilution.
- Related Party Transactions: Note the $0.8 million payable to Baylor College of Medicine (BCM) for manufacturing and services.